Recursion director sells 40,000 shares in RXRX
Recursion Pharmaceuticals director Christopher Gibson converted and sold shares of the company’s stock.
Rhea-AI Filing Summary
Recursion Pharmaceuticals director Christopher Gibson converted and sold shares of the company’s stock. On April 7, he converted 40,000 shares of Class B Common Stock into 40,000 shares of Class A Common Stock and then sold 40,000 Class A shares at $3.10 per share in an open-market transaction.
The trades were made pursuant to a Rule 10b5-1 trading plan adopted on May 12, 2025. Following these transactions, he directly holds 906,556 shares of Class A Common Stock and 4,443,334 shares of Class B Common Stock, while various family entities no longer show Class B holdings in this filing.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Class B Common Stock | 40,000 | $0.00 | $0.00 |
| Conversion | Class A Common Stock | 40,000 | $0.00 | $0.00 |
| Sale | Class A Common Stock | 40,000 | $3.10 | $124K |
| holding | Class B Common Stock | -- | -- | -- |
| holding | Class B Common Stock | -- | -- | -- |
| holding | Class B Common Stock | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
Footnotes (10)
- F1. Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
- F2. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025.
- F3. The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager.
- F4. The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager.
- F5. The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee.
- F6. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
- F7. The option vests as to one forty-eighth (1/48th) of the original 666,898 shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
- F8. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
- F9. The option, originally for 416,350 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
- F10. The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
Key Figures
Key Terms
Rule 10b5-1 trading plan financial
Class B Common Stock financial
Class A Common Stock financial
derivative security financial
Stock Option (Right to Buy) financial
FAQ
What insider transaction did RXRX director Christopher Gibson report?
Was the RXRX insider sale made under a Rule 10b5-1 trading plan?
What RXRX holdings does Christopher Gibson report after these transactions?
What is the relationship between RXRX Class B and Class A Common Stock in this filing?
Does Christopher Gibson still hold RXRX stock options after this Form 4?
AI-generated analysis. How Rhea-AI works. Not financial advice.